🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Patients With Congenital Myasthenic Syndrome Will be Treated With Umbilical or Placental Derived Mesenchymal Stem Cell Exosome Solution

RecruitingPhase 1Ages 18 Years - anyAllThe Foundation for Orthopaedics and Regenerative …
NCT07226726 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with Congenital Myasthenic Syndrome will be treated with Umbilical or Placental Derived Mesenchymal Stem Cell Exosome solution.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician. * Patients must be able to provide informed consent, or have a guardian who does. * Patient must be able to travel to the site of treatment. Exclusion Criteria: * Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.
💊

What it tests

  • AlloEx exosomes
📍

Where

2 sites
Prodromos Stem Cell Institute
Naples, United States
Prodromos Stem Cell Institute
Athens, Greece
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy